

## **Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach**

Riffat Mehboob<sup>1</sup>, Fridoon Jawad Ahmad<sup>2</sup>, Ahad Qayyum<sup>3</sup>, Muhammad Asim Rana<sup>3</sup>, Syed Amir Gilani, Muhammad Akram Tariq<sup>4</sup>, Javed Akram<sup>2</sup>

<sup>1</sup>Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan

<sup>2</sup>Department of Physiology, University of Health Sciences, Lahore, Pakistan

<sup>3</sup>Bahria International Hospital, Lahore, Pakistan

<sup>4</sup>Higher Education Department Punjab, Lahore, Pakistan

**Running Title:** Aprepitant for Covid-19 treatment

**Conflict of Interest:** Authors declare no conflict of interest

### **Corresponding author details:**

Prof. Dr. Riffat Mehboob

Research Unit

Faculty of Allied Health Sciences

The University of Lahore

Lahore, Pakistan

mehboob.riffat@gmail.com

## **Abstract:**

**Background:** Corona virus infection is a respiratory infection, compromising the normal breathing in critical patients by damaging the lungs. Researches are ongoing to find an efficient treatment strategy for this disease by either inactivating the virus or boosting the immune system of patient or by managing the cytokine storm.

**Aim:** To evaluate the clinical outcomes of Substance P receptor Neurokinin 1 antagonist in Covid-19 patients against the usual treatments as controls.

**Patients and Methods:** It is a randomized clinical trial, open label, having two arms, one receiving normal management and care while other receiving Neurokinin-1 Receptor antagonist, Aprepitant, in addition. Dexamethasone, a corticosteroid is also administered orally to both the groups. PCR positive, hospitalized patients with more than 18 years of age, both genders, moderate to critical phase were included. 18 patients were randomly allocated in both arms, having 10 in group A and 8 in group B. Lab investigations were performed in both the groups before and after the intervention. We report preliminary results for the comparison of Aprepitant 80 mg given once daily for 3-5 days vs routine management. The primary outcome was total in hospital days and duration of disease.

**Results:** Mean age of patients in group A was  $47.63 \pm 12.07$  years while  $60.90 \pm 9.75$  years in group B. There were 3/8 males in group A and 8/10 in group B. There were 2 critical patients in group A and 5 in group B. Biochemical and hematological parameters in both groups didn't show much difference except the C-reactive protein reduction in the intervention group, indicative of a reduced inflammation. Oxygen saturation also improved but more patients should be enrolled to get a statistically significant data. One patient was discharged from each group within 5 days and one patient expired in each.

**Conclusions:** It is a pilot study but the findings give a strong clue for the therapeutic potential of Aprepitant. Patients who received a combination therapy of Aprepitant and Dexamethasone were recovered earlier and showed improved clinical outcomes, laboratory findings and reduced C-reactive protein which is an inflammatory marker. We suggest here a study on larger sample size to get a deeper insight of its potential and efficacy. It may be more effective in severe to critical patients having respiratory difficulties.

## **Key words:**

Covid-19 infection, treatment, dexamethasone, Neurokinin-1 Receptor, Substance P, Trigeminal nerve

## Introduction

Novel Coronavirus infection (Covid-19) has become a pandemic in these days. It is an acute respiratory and infectious disease with no etiology and treatment known. It is continuously causing losses of precious lives and economy at a global scale on daily basis. It is need of the hour to find some treatment strategy by either preparing a vaccine or medicine or to boost the immune system. Currently, only management and prevention strategies for the spread of infection are emphasized but there is no treatment available. Different clinical trials are undergoing to evaluate the anti-viral and anti-inflammatory effects of certain drugs but still there are no concrete findings.

Substance P (SP) is a neurotransmitter and neuromodulator, released from the trigeminal nerve of brainstem as a result of nociception<sup>1</sup>. SP is the most common neuropeptide in the airway<sup>2</sup>. Coronavirus enters through the mouth, nose, eyes mainly reaching the lungs through trachea. Substance P (SP) is also released in these regions through non-neuronal cells such as immune cells. It is also released from trigeminal nerve as a result of nociception. Substance P initiates the cytokine storming via binding to its receptor neurokinin-1 and many inflammatory mediators are released. If Substance P release is reduced by Neurokinin-1 receptor antagonist, may control the cytokine storming and hence the hyper-responsiveness of the respiratory tract through reduction in cytokine storming<sup>3</sup>.

It may be directly related to the respiratory illness as is in Covid-19 infection. It may be responsible for the increased inflammation and the signature symptoms associated with this disease. It is the main switch that need to be switched off on urgent basis by using the Neurokinin-1 Receptor (NK-1R) antagonist, Aprepitant. NK-1R is the receptor of SP and responsible for its functionality. In most complicated cases of Covid-19 infection, the clinical manifestations included fever, cough, fatigue, muscular pain, sputum production, loss of smell, shortness of breath, joint pain, sore throat, head ache, vomiting and pink eyes. In severe cases it may lead to respiratory failure, organ failure, and eventually death.

SP is present in a large amount in the CNS and the peripheral nervous system<sup>4</sup>. In neurons, SP is expressed in the soma. Once synthesized, SP is transported in large dense-core vesicles (LDCVs) and the peptide is released through the exocytosis of LDCVs either at axonal terminals or at the neuronal soma<sup>5</sup>. SP is also released by immune cells such as mast cells, macrophages, dendritic cells, T lymphocytes, neutrophils and eosinophils<sup>6</sup>. Substance P mediates interactions between neurons and immune cells, with nerve-derived substance P modulating immune cell proliferation rates and cytokine production<sup>7</sup>. Once exocytosed, SP binds to membrane-bound SP receptor expressed either on the same

cell or on the neighboring cells. Unbound SP can be degraded by a cell surface metalloendopeptidase named neprilysin, and thereby suggests a shorter half-life of SP in tissues<sup>8</sup>. However, SP can prolong its half-life by interacting with fibronectin<sup>9</sup>. In support, SP is reported to be more stable in blood plasma<sup>10</sup>. Thus, SP may form a complex with other molecules to prolong its half-life in tissue or in the blood.

Neurokinin signaling is involved in many inflammatory processes. NK-1R is a 7-transmembrane domain, G-protein coupled receptor with highest affinity for SP. Its full length form has 407 amino acids. It is present on many cell types in the body including the vascular endothelium and lymphatics, fibroblasts, white blood cells, neurons, cardioventillatory regulatory centers and phrenic nuclei controlling the diaphragm and respiration after binding to SP.<sup>11</sup> It is localized in brainstem nuclei controlling the rhythmic control.<sup>12</sup> SP-NK1-R complex, once formed, initiates a signaling cascade and produces inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG)<sup>13</sup>. Importantly, the macrophages and other immune cells produce inflammatory mediators by activation of NF- $\kappa$ B and releases the proinflammatory cytokines.<sup>14</sup> NK-1R manifests systemic inflammation as fever via cytokine-cyclooxygenase 2 prostaglandin E2 axis<sup>15</sup>.

Common and initial symptoms of Covid-19 infection include sore throat, loss of sense of smell and taste, pain in eyes, headache and flue<sup>16</sup> and similar functions are carried out by SP once it is released from trigeminal ganglion via TrN. It provides somatosensory innervation to the orofacial region and has three branches: ophthalmic (V1), maxillary (V2) and mandibular (V3). So any alteration in its secretion in response to viral infection may result in symptoms in orofacial region<sup>17</sup>. Vagal C fibers in larynx and upper airways secrete SP and cause cough. NK-1R antagonists are found to be helpful in reducing the refractory cough frequency.<sup>18,19</sup> A study was conducted to assess the role of SP in clinical cough in humans. Serum SP levels were observed to be elevated in patients with persistent cough as compared to healthy controls. It was attributed to airway sensitivity in asthmatic cough.<sup>20</sup> Previous studies from our own work have also revealed the involvement of SP and NK-1R in cardiorespiratory control<sup>21</sup>, sleep wake cycle<sup>21</sup>, inflammation<sup>22</sup> and involvement in fatal outcomes<sup>17</sup>. Some of our recent unpublished work also reports similar findings of SP/NK-1R involvement in inflammation<sup>23</sup>, pain, pathologies, sudden deaths<sup>24</sup> etc. SP and NK-1R are also found to be involved in immunology<sup>7, 15</sup>, lung inflammation<sup>2, 7</sup>, respiratory network stability<sup>25, 26</sup>, heart failure<sup>27</sup> and neurological and psychiatric disorders<sup>28</sup>. An increased expression of SP in plasma of patients with other viral infections such as HIV and HSV is also well documented<sup>16, 29</sup>.

SP via its tachykinin receptor, Neurokinin-1 (NK-1R) may be responsible for inflammation in Covid-19 infection. It may be potentially the main trigger which further activate the immune system. If blocked, it may stop the cascade of inflammation and hence, the infection too. The virus itself is not causing mortality but the respiratory failure, organ failure or heart attack due to cytokine storming. Hence, we propose Aprepitant in combination with Dexamethasone for the treatment of Covid-19 infection.

## **Methods:**

### **Trial Design and Participants:**

It is an open label, randomized clinical trial conducted at Bahria International Hospital, Lahore, to evaluate the effects of a combination therapy including Dexamethasone and Aprepitant in hospitalized patients with Covid-19. The trial was conducted in accordance with the principles of the International Conference on Harmonization Good Clinical Practice guidelines and approved by the Bahria International Hospital Ethic Committee and informed consent was obtained from the patients.

### **Randomization:**

Case report form included demographics, major comorbidities, medication already being administered. Patients were divided randomly into two arms Control (A) and Interventioanl (B). Both the arms received routine management including Dexamethasone 20mg, but one arm received Aprepitant capsule 80mg once a day as an addition for 3-5 days depending on the condition of patient. Inclusion criteria was admitted patients above 18 years, both genders, lab confirmed Covid-19 positive based on PCR, more than 72 hours since the appearance of first symptoms. Patients with moderate to critical stages were included. Patients with respiratory diseases other than Covid-19 infection and pregnant females were excluded. Primary endpoint was total in hospital days and the duration of disease. Patients and care givers were not blinded to the allocated treatment. Lab investigations including total blood cell count, total leukocyte count, C-reactive protein, D-dimers, lactate dehydrogenase, oxygen saturation was performed on daily basis to monitor the status of patient.

## **Results:**

### **Patients:**

Mean age of patients in the group A (control, non-aprepitant) was while  $47.63 \pm 12.07$  years while  $60.90 \pm 9.75$  years in group B (Aprepitant). There were 3 males and 5 females in A while 8 males and 2 females in B. In group A, 3 mild, 3 severe and 2 critical. 2 patients in group B were mild, 3 severe and 5 critical. The mean WBC in group A was  $15.31 \pm 13.87$  (P-value  $>0.05$ ) while in group B was  $15.10 \pm 6.01$ . The mean WBC in group A was  $15.31 \pm 13.87$  (P-value  $>0.05$ ) while in group B was

15.10 ± 6.01. The mean PLT in group A was 250 ± 95039 (P-value >0.05) while in group B was 271.70 ± 110.11. The mean CRP in group A was 7.877 ± 10.84 (P-value >0.05) while in group B was 12.12 ± 16.39. The mean Ferritin in group A was 411.10 ± 289.42 (P-value >0.05) while in group B was 649.7 ± 605.15. The mean D-Dimers in group A was 249.0 ± 158.58 (P-value >0.05) while in group B was 479.6 ± 382.46. The mean LDH in group A was 230.12 ± 56.33 (P-value < 0.05) while in group B was 404.3 ± 304.7 (Table 1). Biochemical and hematological parameters of individual patients along with age and disease severity status is shown in table 2 and 3.

Co-morbidities in 3 patients of group A included depression, anti-phospholipid Syndrome, Amyloid leukemia, 4<sup>th</sup> patient had hyper tension, diabetes & Ischemic heart disease, 5<sup>th</sup> had diabetes, Hodgkin lymphoma, 6<sup>th</sup> had hypertension and end stage renal disease on maintenance hemodialysis. 4 patients of the group A had no other disease. In group B, 2 patients had hyper tension alone, one had hypertension, diabetes, ischemic heart disease and benign prostatic hyperplasia, 3 patients had hypertension, diabetes, ischemic heart disease and carotid artery bypass grafting and one had hypertension, diabetes and ischemic heart disease while 2 had no comorbidity. There were more critical patients in group B. Azithromycin, Remdisivir, Tocilizumab were administered in both the groups as routine management and usual care, irrespective of the group allocation. One patient was discharged in both groups within first 5 days while one patient expired in both groups. It is a preliminary report and detailed study with larger sample size is in progress.

<b>Demographics, clinical characteristics</b>				
<b>Variables</b>	<b>Total</b>	<b>Group A (Non-Aprepitant)</b>	<b>Group B (Aprepitant)</b>	<b>P value</b>
<b>Age</b>	18	47.63 ± 12.07	60.90 ± 9.75	0.20
<b>Gender</b>				
<b>Male</b>	11	3	8	NA
<b>Female</b>	7	5	2	NA
<b>Mild</b>	5	3	2	NA
<b>Severe type</b>	6	3	3	NA
<b>Critical type</b>	7	2	5	NA
<b>Laboratory findings, Mean ± SD</b>				
<b>WBC (1×10<sup>9</sup>/L)</b>	18	15.31 ± 13.87	15.10 ± 6.01	0.965
<b>PLT (1×10<sup>9</sup>/L)</b>	18	250 ± 95039	271.70 ± 110.11	0.677
<b>CRP (mg/l)</b>	18	7.877 ± 10.84	12.12 ± 16.39	0.538
<b>Ferritin</b>	18	411.10 ± 289.42	649.7 ± 605.15	0.322
<b>D-Dimers</b>	18	249.0 ± 158.58	479.6 ± 382.46	0.131
<b>LDH</b>	18	230.12 ± 56.33	404.3 ± 304.7	0.024
WBC: White blood cell count; PLT: Platelet count; CRP: C-reactive protein				

Table 1: Baseline characteristics of demographics, clinical and laboratory findings in Aprepitant group and Non-Aprepitant group

## Discussion:

These initial findings show that a combination therapy of Dexamethasone and Aprepitant is effective in treating severe to critical Covid-19 patients. Dexamethasone is a recently discovered drug for the treatment of critically ill Covid-19 patients. It is previously being used for similar indications such as post surgery or post-chemotherapy emesis, nausea. Previously, it is in use alone as well as a combination therapy with Aprepitant. There are no major side-effects and safe for use in children as well as pregnant females. Rather it is used for lung maturation in premature labor and administered a day to week before delivery<sup>30</sup>. In our recent study, we have also suggested the similar role for aprepitant.<sup>24</sup> It may also improve the respiratory conditions in pre-mature labour as well as Covid-19 patients. We also suggest Ondansetron, a serotonin receptor antagonist along with these two drugs. This medication is already in use for the treatment of nausea and vomiting post chemotherapy. Serotonin is also involved with the nociceptive stimuli along with Substance P in inflammation. It may also be helpful in management of critically ill patients with respiratory problems as a result of Covid-19 infection.

Although mean of all the data is not showing much significant findings but a close look at the data of individual patients reveals a marked reduction in the levels of C-reactive protein in the intervention group B as compared to the group A. It is also noteworthy, that there were more male patients in group A, with less mean age and lesser critical patients which may also affect the results.

SP secreted by the immune cells stimulates Th1 and Th17 autoreactive cells that migrate to the CNS and target nerves<sup>31</sup>. Hence, SP has been observed to be an important player in autoimmune responses. Expression of SP receptors, NK-1R is increased during inflammation, mainly on lymphocytes and macrophages. Hence, SP has a key role in immune system regulation by modulating the chemokines and adhesion molecules<sup>7</sup>. SP promotes angiogenesis by stimulating immune cells<sup>32</sup>. It affects the endothelial cells directly to produce nitric oxide or indirectly by interacting with mast cells and granulocytes<sup>33</sup>.

Neutral endopeptidase (NEP) also known as Enkephalinase is SP degrading enzyme and animal studies have reported a decreased NEP activity in trachea of rats infected with parainfluenza virus type 1, corona virus and *Mycoplasma pulmonis*. NEP depletion in respiratory tract may lead to increased vulnerability to neurogenic inflammation by permitting larger concentrations of SP to reach NK-1R in the respiratory tract. This reduction of NEP activity elicits the pathological responses in

respiratory infections<sup>1</sup>. Although SP is a neurotransmitter but its exocrine role within the respiratory tract is well known<sup>1</sup>. Exogenous SP is involved in the mediation of inflammation in airways<sup>34</sup>, causes smooth muscle contraction<sup>35</sup> and mucous secretion from tracheal glands<sup>36</sup> and increased vascular permeability<sup>37</sup>. Stimulation of sensory nerves by irritants including viruses causes bronchoconstriction<sup>38</sup> and also increases the attachment of neutrophils to the endothelium of venules<sup>39</sup>, leading to inflammation<sup>1</sup>. Several aspects of SP in airways are regulated by NEP<sup>35</sup>. So, it is already a proven fact that respiratory tract infections potentiates the vascular permeability produced by SP due to a decrease in NEP activity in the respiratory tract. The understanding of this mechanism is crucial in treatment of respiratory infections such as Covid-19. Alterations in NEP activity may result in altered SP concentrations in airways and leading to clinical manifestations of respiratory disease<sup>1</sup>.

Hence, dexamethasone, a corticosteroid may modulate immune-mediated lung injury and reduces the progression to respiratory failure and death by mainly affecting the NEP and Aprepitant may block the receptor of SP. Both dexamethasone and Aprepitant are affecting the SP, one by potentiating the SP degrading enzyme and the other by antagonizing the SP receptor, therefore, reducing the SP binding the receptor.

### **Conclusions:**

Substance P (SP) is a possible cause of the initiation of cytokine storming developed in Covid-19 infection and we suggest Neurokinin-1 Receptor antagonist, Aprepitant, as a drug to be used for its treatment. It may help in the management of cytokine storming as well as improving the respiratory outcome in severe to critical patients.

### **References:**

1. Borson DB, Brokaw JJ, Sekizawa K, McDonald DM, Nadel JA. Neutral endopeptidase and neurogenic inflammation in rats with respiratory infections. *J Appl Physiol* (1985). 1989; **66**(6): 2653-8.
2. Li M, Shang YX. Neurokinin-1 receptor antagonist decreases  $[Ca^{2+}]_i$  in airway smooth muscle cells by reducing the reverse-mode  $Na^{+}/Ca^{2+}$  exchanger current. *Peptides*. 2019; **115**: 69-74.
3. Mehboob RA, F.J. . SARS-Corona Virus-2 May Initially Infect Brainstem through Trigeminal Ganglion-Latency May Be Present-A New Perspective Preprints 2020, 2020070015 2020.
4. Hokfelt T, Vincent S, Dalsgaard CJ, Skirboll L, Johansson O, Schultzberg M, et al. Distribution of substance P in brain and periphery and its possible role as a co-transmitter. *Ciba Foundation symposium*. 1982; (91): 84-106.
5. De Camilli P, Jahn R. Pathways to regulated exocytosis in neurons. *Annual review of physiology*. 1990; **52**: 625-45.
6. Suvas S. Role of Substance P Neuropeptide in Inflammation, Wound Healing, and Tissue Homeostasis. *J Immunol*. 2017; **199**(5): 1543-52.
7. Mashaghi A, Marmalidou A, Tehrani M, Grace PM, Pothoulakis C, Dana R. Neuropeptide substance P and the immune response. *Cellular and molecular life sciences : CMLS*. 2016; **73**(22): 4249-64.
8. Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 1989; **3**(2): 145-51.
9. Rameshwar P, Oh HS, Yook C, Gascon P, Chang VT. Substance p-fibronectin-cytokine interactions in myeloproliferative disorders with bone marrow fibrosis. *Acta haematologica*. 2003; **109**(1): 1-10.
10. Corbally N, Powell D, Tipton KF. The binding of endogenous and exogenous substance-P in human plasma. *Biochemical pharmacology*. 1990; **39**(7): 1161-6.
11. Graefe S, Mohiuddin SS. *Biochemistry, Substance P*. StatPearls. Treasure Island (FL); 2020.
12. Mazzone SB, Geraghty DP. Respiratory actions of tachykinins in the nucleus of the solitary tract: effect of neonatal capsaicin pretreatment. *British journal of pharmacology*. 2000; **129**(6): 1132-9.
13. Ramkissoon SH, Patel HJ, Taborga M, Rameshwar P. G protein-coupled receptors in haematopoietic disruption. *Expert opinion on biological therapy*. 2006; **6**(2): 109-20.
14. Bost KL. Tachykinin-mediated modulation of the immune response. *Frontiers in bioscience : a journal and virtual library*. 2004; **9**: 3331-2.
15. Pakai E, Tekus V, Zsiboras C, Rumbus Z, Olah E, Keringer P, et al. The Neurokinin-1 Receptor Contributes to the Early Phase of Lipopolysaccharide-Induced Fever via Stimulation of Peripheral Cyclooxygenase-2 Protein Expression in Mice. *Frontiers in immunology*. 2018; **9**: 166.
16. Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. *European review for medical and pharmacological sciences*. 2020; **24**(6): 3404-10.
17. Mehboob R. Substance P/Neurokinin 1 and Trigeminal System: A Possible Link to the Pathogenesis in Sudden Perinatal Deaths. *Frontiers in neurology*. 2017; **8**: 82.
18. Badri H, Smith JA. Emerging targets for cough therapies; NK1 receptor antagonists. *Pulmonary pharmacology & therapeutics*. 2019; **59**: 101853.

19. Smith J, Allman D, Badri H, Miller R, Morris J, Satia I, et al. The Neurokinin-1 Receptor Antagonist Orvepitant Is a Novel Antitussive Therapy for Chronic Refractory Cough: Results From a Phase 2 Pilot Study (VOLCANO-1). *Chest*. 2020; **157**(1): 111-8.
20. Otsuka K, Niimi A, Matsumoto H, Ito I, Yamaguchi M, Matsuoka H, et al. Plasma substance P levels in patients with persistent cough. *Respiration; international review of thoracic diseases*. 2011; **82**(5): 431-8.
21. Lavezzi AM, Mehboob R, Matturri L. Developmental alterations of the spinal trigeminal nucleus disclosed by substance P immunohistochemistry in fetal and infant sudden unexplained deaths. *Neuropathology*. 2011; **31**(4): 405-13.
22. Mehboob R, Tanvir I, Warraich RA, Perveen S, Yasmeen S, Ahmad FJ. Role of neurotransmitter Substance P in progression of oral squamous cell carcinoma. *Pathol Res Pract*. 2015; **211**(3): 203-7.
23. Mehboob R HA, Perveen S, Gilani SA, Waseem H, Ahmad FJ and Akram J. Intense expression of Neurokinin-1 Receptor is associated with Urothelial carcinoma. Submitted to *Pathology*. 2020.
24. Mehboob GS, Hassan A, Tirmazi AH, Ahmad FJ, Babar ME, Akram SJ and Akram J. Elevated Neurokinin 1-Receptor Expression in uterine products of conception is associated with first trimester Miscarriages. Submitted to *Frontiers in Physiology*. 2020.
25. Szereda-Przestaszewska M, Kaczynska K. Serotonin and substance P: Synergy or competition in the control of breathing. *Auton Neurosci*. 2020; **225**: 102658.
26. Yeh SY, Huang WH, Wang W, Ward CS, Chao ES, Wu Z, et al. Respiratory Network Stability and Modulatory Response to Substance P Require Nalcn. *Neuron*. 2017; **94**(2): 294-303 e4.
27. Dehlin HM, Levick SP. Substance P in heart failure: the good and the bad. *Int J Cardiol*. 2014; **170**(3): 270-7.
28. Iftikhar K, Siddiq A, Baig SG, Zehra S. Substance P: A neuropeptide involved in the psychopathology of anxiety disorders. *Neuropeptides*. 2020; **79**: 101993.
29. Douglas SD, Ho WZ, Gettes DR, Cnaan A, Zhao H, Leserman J, et al. Elevated substance P levels in HIV-infected men. *AIDS*. 2001; **15**(15): 2043-5.
30. Grgic G, Fatusic Z, Bogdanovic G. [Stimulation of fetal lung maturation with dexamethasone in unexpected premature labor]. *Med Arh*. 2003; **57**(5-6): 291-4.
31. Vilisaar J, Kawabe K, Braitch M, Aram J, Furtun Y, Fahey AJ, et al. Reciprocal Regulation of Substance P and IL-12/IL-23 and the Associated Cytokines, IFN $\gamma$ /IL-17: A Perspective on the Relevance of This Interaction to Multiple Sclerosis. *Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology*. 2015; **10**(3): 457-67.
32. Ziche M, Morbidelli L, Pacini M, Geppetti P, Alessandri G, Maggi CA. Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. *Microvascular research*. 1990; **40**(2): 264-78.
33. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. *The Journal of clinical investigation*. 1994; **94**(5): 2036-44.
34. Lundberg JM, Hokfelt T, Martling CR, Saria A, Cuello C. Substance P-immunoreactive sensory nerves in the lower respiratory tract of various mammals including man. *Cell and tissue research*. 1984; **235**(2): 251-61.
35. Sekizawa K, Tamaoki J, Nadel JA, Borson DB. Enkephalinase inhibitor potentiates substance P- and electrically induced contraction in ferret trachea. *J Appl Physiol* (1985). 1987; **63**(4): 1401-5.

36. Baker AP, Hillegass LM, Holden DA, Smith WJ. Effect of kallidin, substance P, and other basic polypeptides on the production of respiratory macromolecules. *The American review of respiratory disease*. 1977; **115**(5): 811-7.
37. Lundberg JM, Saria A, Brodin E, Rosell S, Folkers K. A substance P antagonist inhibits vagally induced increase in vascular permeability and bronchial smooth muscle contraction in the guinea pig. *Proceedings of the National Academy of Sciences of the United States of America*. 1983; **80**(4): 1120-4.
38. Sellick H, Widdicombe JG. Stimulation of lung irritant receptors by cigarette smoke, carbon dust, and histamine aerosol. *Journal of applied physiology*. 1971; **31**(1): 15-9.
39. McDonald DM, Mitchell RA, Gabella G, Haskell A. Neurogenic inflammation in the rat trachea. II. Identity and distribution of nerves mediating the increase in vascular permeability. *Journal of neurocytology*. 1988; **17**(5): 605-28.

### **Competing Interest Statement:**

The authors have declared no competing interest.

### **Clinical Trial:**

This trial is registered in [clinicaltrials.gov](https://clinicaltrials.gov) (NCT04468646).

### **Funding:**

No funding has been received for this study

### **Author Declarations**

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial was conducted in accordance with the principles of the International Conference on Harmonization Good Clinical Practice guidelines and approved by the Bahria International Hospital Ethic Committee.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as [ClinicalTrials.gov](https://clinicaltrials.gov). I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided ([ClinicalTrials.gov](https://clinicaltrials.gov) Identifier: NCT04468646).

